Novartis: Kisqali's efficacy confirmed in breast cancer.
(CercleFinance.com) - Novartis revealed last week-end updated findings from a phase III study that reinforced the efficacy and safety of Kisqali in women with advanced breast cancer.
After an additional 11 months of follow-up, a median progression-free survival of 25.3 months was observed for Kisqali plus hormonal therapy letrozole and 16 months for letrozole alone.
The study focused on postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
These data have been be presented on Sunday at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Novartis also presented results from a phase II study showing a durable survival benefit for some patients with BRAF V600 mutation-positive metastatic melanoma when treated with the combination of Tafinlar and Mekinist.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
After an additional 11 months of follow-up, a median progression-free survival of 25.3 months was observed for Kisqali plus hormonal therapy letrozole and 16 months for letrozole alone.
The study focused on postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
These data have been be presented on Sunday at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Novartis also presented results from a phase II study showing a durable survival benefit for some patients with BRAF V600 mutation-positive metastatic melanoma when treated with the combination of Tafinlar and Mekinist.
Copyright (c) 2017 CercleFinance.com. All rights reserved.